Inclusion Criteria:

1. Patient with histological proven colorectal cancer.

2. Operable liver metastases according to preoperative imagery. Operability is the
possibility of treatment by resection and/or local destruction (radiofrequency,
cryotherapy…).

3. Patient treated or not with preoperative chemotherapy.

4. With or without extra-hepatic metastases.

5. Age ≥ 18 years.

6. Radiological assessment by CT and MRI liver and TEPscan within six weeks before
surgery.

7. Patient affiliated to the Social Security system.

8. Signed informed consent.

Exclusion Criteria:

1. Known hypersensitivity to sulfur hexafluoride or another component of SonoVue®.

2. Patients with recent acute coronary syndrome or suffering from unstable ischemic
heart disease, especially: evolving myocardial infarction, unstable angina during the
last 7 days, recent coronary intervention or another factor suggesting clinical
instability, acute heart failure, class III or IV heart failure, severe arrhythmias.

3. Patients with right-to-left shunt, severe pulmonary arterial hypertension,
uncontrolled systemic hypertension, as patients suffering from respiratory distress
syndrome.

4. Pregnant and lactating women.

5. Patients with contraindication for a CT scan, a MRI or a TEP with contrast.

6. Patients with indication of two step liver surgery.

7. Patients already included in the study.

8. Patient who couldn't be treated or followed up according to study criteria for
psychological, social, family or geographical reasons. Patient deprived of liberty or
under guardianship.